MECP2 Duplication Syndrome
MECP2 Duplication Syndrome (MDS) is a rare genetic disorder caused by duplications of the MECP2 gene, leading to developmental delays, intellectual disability, and various neurological symptoms.
We are testing a new treatment called ION440 to see if it is safe and well-tolerated in patients with MECP2 Duplication Syndrome. This study will also look at how the drug moves through the body.
Health conditions and diseases that the clinical trial is designed to study and treat.
MECP2 Duplication Syndrome (MDS) is a rare genetic disorder caused by duplications of the MECP2 gene, leading to developmental delays, intellectual disability, and various neurological symptoms.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.